Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aliconazole SCHEMBL2109608 | 1.00 | CYP19A1 (0.47) | CYP19A1ADRA2CCA12CA1CA2 | |
| Aliconazole SCHEMBL29532590 | 1.00 | CYP19A1 (0.47) | CYP19A1ADRA2CCA12CA1CA2 | |
| SCHEMBL11719546 | 0.93 | CYP19A1 (0.47) | CYP19A1ADRA2CCA12CA1CA2 | |
| SCHEMBL2355400 | 0.90 | CYP19A1 (0.46) | CYP19A1ADRA2CCA12CA1CA2 | |
| SCHEMBL2355395 | 0.90 | CYP19A1 (0.46) | CYP19A1ADRA2CCA12CA1CA2 | |
| SCHEMBL2355399 | 0.90 | CYP19A1 (0.46) | CYP19A1ADRA2CCA12CA1CA2 | |
| SCHEMBL11722279 | 0.88 | CYP3A4 (0.52) | CYP19A1ADRA2CCA12CA1CA2 | |
| Ethylene Glycol SCHEMBL11038393 | 0.84 | CYP3A4 (0.49) | CYP19A1ADRA2CCA12CA1CA2 | |
| SCHEMBL11724328 | 0.83 | CYP19A1 (0.59) | CYP19A1CYP2A6CYP11B1CYP11B2CYP2B6 | |
| SCHEMBL11723422 | 0.80 | CYP19A1 (0.62) | CYP19A1CYP2A6CYP11B1CYP11B2CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ROHM AND HAAS COMPANY | 2004-12-16 | — | — | US | claimed |
| CN-1441790-A | Enhanced propertied pharmaceuticals | ROHM & HAAS (US) | 2003-09-10 | — | — | CN | claimed |
| EP-1272463-A1 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001054481-A2 | ENHANCED PROPERTIED PHARMACEUTICALS | ROHM AND HAAS COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-4057545-A | FUNGICIDE, BACTERICIDE | NORDMARK-WERKE GMBH HAMBURG (DT) | 1977-11-08 | — | — | US | claimed |
| US-20240226067-A9 | ANTI-FIBROTIC THERAPIES | THE JOHNS HOPKINS UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| US-20240131006-A1 | ANTI-FIBROTIC THERAPIES | UNIV JOHNS HOPKINS (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2022187287-A1 | ANTI-FIBROTIC THERAPIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| EP-0719552-A2 | Pharmaceutical composition comprising a quinone derivative or a hydroquinone thereof for treating dermatitis | Takeda Chemical Industries, Ltd. (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-4894375-A | FUNGISTATS, KETOCONAZOLE | MERCK & CO., INC. (US) | 1990-01-16 | — | — | US | disclosed |
| US-4871741-A | FUNGICIDES; KETOCONAZOLE AND MEVINOLINIC ACID | MERCK & CO., INC. (US) | 1989-10-03 | — | — | US | disclosed |
| US-4782059-A | Method of controlling mycotic infections and compositions therefor | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254182-A1 | Enhanced propertied pharmaceuticals | ABCB1, ABCB11, ABCG2 | CYP19A1 946/4885ADRA2C 1822/4885CA12 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.